07:08 AM EDT, 09/11/2024 (MT Newswires) -- Arch Biopartners ( ACHFF ) on Wednesday said that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide, the company's leading drug candidate targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

The clinical team at the University of Calgary Cumming School of Medicine is completing final preparations and training to start patient recruitment in September. University Health Network and Unity Health Toronto are also working on final ethics and hospital approvals to start patient recruitment at two hospitals.

The trial continues to recruit patients at five clinical sites in Turkey.